Immatics' PRAME TCR Therapy Induces Remission in Pediatric Nephroblastoma
Analysis based on 8 articles · First reported Apr 17, 2026 · Last updated Apr 17, 2026
This medical breakthrough by Immatics, demonstrating deep remission in a pediatric cancer patient with no other treatment options, is expected to significantly boost investor confidence in Immatics' PRAME-directed cell therapies. It highlights the potential for new treatment options in pediatric oncology, likely leading to increased stock valuation for Immatics and positive sentiment across the biotechnology sector.
Immatics N.V. announced that an abstract highlighting a pediatric patient treated with their PRAME-directed cell therapy achieved deep and durable remission from advanced metastatic nephroblastoma. The 17-year-old patient, who had exhausted all other treatment options, received an individual experimental treatment at Hopp Children s Cancer Center Heidelberg (KiTZ) and University Hospital Heidelberg (UKHD) using Immatics' PRAME T-cell receptor (TCR). The treatment resulted in marked regression of liver, lung, and brain metastases, with the response ongoing at six months. Dr. Christian M. Seitz, Group Leader at Hopp Children s Cancer Center Heidelberg (KiTZ), will present these findings at the American Association for Cancer Research (AACR) Annual Meeting 2026. This success underscores the therapeutic potential of PRAME TCR T-cell therapy in pediatric solid tumors and supports Immatics' plans for further clinical evaluation in this patient population.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard